| Drug Type Universal CAR-T, Induced pluripotent stem cells (iPSC) | 
| Synonyms- | 
| Target | 
| Action agonists, inhibitors | 
| Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), BCMA inhibitors(B-cell maturation protein inhibitors), CD58 inhibitors(Lymphocyte function-associated antigen 3 inhibitors) | 
| Therapeutic Areas | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Leukemia | Preclinical | United States  | 08 Dec 2024 | |
| Lymphoma | Preclinical | United States  | 08 Dec 2024 | 





